TrialJournal for immunotherapy of cancer2020

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.

Michael Overman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.